At its meeting on 15 July 2024, the Transparency Council adopted position No. 66/2024 on the evaluation of the drug Cabometyx (cabozantinib) under the drug program “Treatment of patients with renal cell carcinoma (ICD-10: C64)” in combination with nivolumab